Skip to Content

Posts tagged with "Academia (vs. Industry)"

  • Academia (vs. Industry)

    Gonna Focus on Re-Engineering the Tools for the Process

    I have tried several times to get my hands around what NIH head Francis Collins is talking about here (note: open-access article), but I now admit defeat. Allow me to quote a bit, and we’ll see if anyone else out there has more luck: We have seen a deluge of new discoveries in the last… Read More
  • Academia (vs. Industry)

    New Cures! Faster! Faster!

    I wrote here the other day about the NIH’s new translational medicine plans. The New York Times article that brought this to wide attention didn’t go over well with director Francis Collins, who ended up trying to disabuse people of the idea that the NIH was going to set up its own drug company. But… Read More
  • Academia (vs. Industry)

    The NIH’s New Drug Discovery Center: Heading Into the Swamp?

    I’ve been meaning to comment on the NIH’s new venture into drug discovery, the National Center for Advancing Translational Sciences. Curious Wavefunction already has some thoughts here, and I share his concerns. We’re both worried about the gene-o-centric views of Francis Collins, for example: Creating the center is a signature ef… Read More
  • Academia (vs. Industry)

    Friday Mental Health Break: “Bad Project”

    A reader sent this along to me, and I figured that many folks who are in (or have been through) academia can relate. This is the Hui Zheng lab at Baylor, with their Gaga-esque production of. . .Bad Project: Congratulations to them. It’s a good thing that there was no YouTube back when I was… Read More
  • Academia (vs. Industry)

    Chemistry Jobs Roundtable: What About Tenure?

    The latest post in the week-long blog roundtable on chemistry jobs is up over at Chembark, and it looks at the academic side: is tenure useful? If so, do its disadvantages outweigh the benefits? What would happen if we ditched it (and could we)?… Read More
  • Academia (vs. Industry)

    Design Your Own Lab Course

    Here’s an interesting question from a reader in academia. At his institution, they’re thinking about rewriting the introductory organic lab syllabus. “Rather than put what the faculty would like to see in it”, he writes, “what would your readers like to see in it?” The questions he raises include these: What orga… Read More
  • Academia (vs. Industry)

    And One Was Just Right?

    I’ve been reading an interesting new paper from Stuart Schreiber’s research group(s) in PNAS. But I’m not sure if the authors and I would agree on the reasons that it’s interesting. This is another in the series that Schreiber has been writing on high-throughput screening and diversity-oriented synthesis (DOS). As mentioned… Read More
  • Academia (vs. Industry)

    Where Drugs Come From: By Country

    The same paper I was summarizing the other day has some interesting data on the 1998-2007 drug approvals, broken down by country and region of origin. The first thing to note is that the distribution by country tracks, quite closely, the corresponding share of the worldwide drug market. The US discovered nearly half the drugs… Read More
  • Academia (vs. Industry)

    Where Drugs Come From: The Numbers

    We can now answer the question: “Where do new drugs come from?”. Well, we can answer it for the period from 1998 on, at any rate. A new paper in Nature Reviews Drug Discovery takes on all 252 drugs approved by the FDA from then through 2007, and traces each of them back to their… Read More
  • Academia (vs. Industry)

    Another Set of Eyes

    Via Avik Roy at Forbes, there’s news of a deal between Pfizer and Washington University at St. Louis. The company is giving the university “unprecedented access” to what they say is a list of more than 500 drugs and failed drug candidates, and letting them tear into them in an effort to find out what… Read More
...91011...